Report Overview

Indian Cancer Supportive Care Drugs market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

In India the incidence of patients with cancer in India among males was 679,421 (94.1 per 100,000) and among females 712,758 (103.6 per 100,000) for the year 2020. One in 68 males (lung cancer), 1 in 29 females (breast cancer), and 1 in 9 Indians will develop cancer during their lifetime The projected 5 most common cancers in 2020 for males (lung, mouth, prostate, tongue, and stomach) constitute 36% of all cancers and for females (breast, cervix uteri, ovary, corpus uteri, and lung) constitute 53% of all cancers. According to a report by the World Health Organization (WHO), India has estimated 1.16 million new cancer cases in 2018. Cancer treatment includes chemotherapy, targeted therapy, radiation therapy, and hormone replacement therapy. These therapies come with significant advantages and side effects. Cancer supportive care drugs used to aid the treatment and reduce the side effects associated with the cancer drugs and treatment. Growing demand for various cancer therapies, owing to high prevalence of the disease is expected to drive the Indian cancer supportive care drugs market growth during the forecast period.



Market Drivers

The increasing prevalence of cancer, several organizations and government are taking the initiations to manufacture cancer supportive care products to meet the increasing need for the treatment of cancer and presently, various products are going through clinical trials that can be utilized for the treating of several side effects of the cancer therapy, which in turn is expected to propel the growth of the cancer supportive care products market. Crucially, the cancer-supporting therapeutics market is driving the growing incidence of cancer illness, the quickly growing biopharmaceutical sector, the growing scholarly & clinical study activities, increased cooperation among awareness-raising organizations, lifestyle changes, advances in healthcare, new therapeutics and increased per capita revenue. Increasing development has led to significant progress in cancer research and therapy in the biopharmaceutical sector. Drug discovery developments have led in lower death rates among patients suffering from cancer. Improvements were made in cancer pain management, however because of bad evaluation by doctors and the absence of appropriate understanding of new medicines and therapy these improvements have been underutilized.